Lopid Related Published Studies
Well-designed clinical trials related to Lopid (Gemfibrozil)
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. [2011.05]
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. [2011.04]
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. [2011.03]
The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. [2011.02]
The effect of gemfibrozil, niacin and cholestyramine combination therapy on
metabolic syndrome in the Armed Forces Regression Study. [2011]
Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. [2010.09]
Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. [2010.08]
Gemfibrozil in late preterm and term neonates with moderate jaundice: a randomized controlled trial. [2009.12]
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. [2009.12]
Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. [2009.05]
Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. [2009.02.01]
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. [2008.10]
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. [2008.09]
Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). [2008.02]
The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. [2006.08]
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. [2006.06]
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. [2006.03.28]
[Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor] [2006]
Effect of gemfibrozil on the pharmacokinetics of pioglitazone. [2005.12]
Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. [2005.11.01]
Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. [2005.08]
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. [2005.08]
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. [2005.08]
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. [2005.05]
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. [2005.04]
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. [2005.03]
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. [2005.01.15]
Comparative bioavailability study with two gemfibrozil tablet formulations in healthy volunteers. [2005]
Well-designed clinical trials possibly related to Lopid (Gemfibrozil)
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. [2011.08.01]
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study. [2010.12]
Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. [2010.04]
Myopathy with statin-fibrate combination therapy: clinical considerations. [2009.09]
Hypertriglyceridemia and hypercholesterolemia: effects of drug treatment on fatty acid composition of plasma lipids and membranes. [2008.04]
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). [2007.09]
A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. [2007.06]
Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. [2006.11.23]
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. [2006.11.01]
Long term clinical trials: how much information do participants retain from the informed consent process? [2006.10]
The sense of coherence and incidence of cancer--role of follow-up time and age at baseline. [2006.08]
Evaluation of laboratory monitoring alerts within a computerized physician order entry system for medication orders. [2006.07]
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. [2005.01.18]
Other research related to Lopid (Gemfibrozil)
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. [2011.10]
Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin. [2011.03]
Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. [2011.02]
Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. [2011.01.15]
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. [2011]
Erythema multiforme associated with gemfibrozil monotherapy. [2010.01]
Gemfibrozil-induced myositis in a patient with normal renal function. [2010.01]
Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. [2009.12]
Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. [2009.10.01]
CYP2C8 Activity Recovers Within 96 Hours After Gemfibrozil Dosing: Estimation of CYP2C8 Half-life Using Repaglinide as an In Vivo Probe. [2009.09.22]
Recovery time in a case of gemfibrozil and simvastatin-associated rhabdomyolysis. [2009.08]
Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice. [2009.07.07]
Interaction between gemfibrozil and warfarin: case report and review of the literature. [2009.06]
Effects of Diet and Gemfibrozil on Posttransplant Hyperlipidemia in Renal Transplant Recipients. [2009.02]
Increase in tiagabine serum concentration with coadministration of gemfibrozil. [2009.02]
Gemfibrozil, stretching arms beyond lipid lowering. [2009]
Investigation on different levels of in vitro-in vivo correlation: gemfibrozil immediate release capsule. [2008.09]
Micronization of gemfibrozil by reactive precipitation process. [2008.08.06]
Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. [2008.05]
Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. [2008.04.16]
The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo. [2008.03.19]
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. [2008.01.01]
Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. [2008.01]
Gemfibrozil ingestions reported to Texas poison control centers, 2000-2005. [2007.12]
Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. [2007.10]
Increased survival after gemfibrozil treatment of severe mouse influenza. [2007.08]
Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. [2007.05]
Therapeutic rationale of combining therapy with gemfibrozil and simvastatin. [2007.03]
Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: an opportunity for pharmacists. [2007.01]
Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. [2006.04.10]
Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects. [2006.04]
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. [2006.04]
Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. [2006]
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia. [2006]
Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. [2005.12]
Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. [2005.10]
Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration. [2005.07]
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. [2005.01.01]
[Preparation and investigation of gemfibrozil + dimethyl-beta-cyclodextrin products and solid dosage forms] [2005]
Other possibly related research studies
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. [2007.01.08]
Comparison of effects of fibrates in patients with hypertriglyceridemia. [2006.09]
Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. [2006.12]
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. [2006.09]
Peroxisome proliferator-activated receptors increase human sebum production. [2006.09]
[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States] [2005]
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. [2006.01]
[Drug combinations: statins and fibrates] [2005.10]
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. [2006.01]
Differential associations of statin and fibrate treatment with carotid arterial remodeling. [2005.11]
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). [2006.07]
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents. [2006.01.01]
Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat? [2005.10]
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. [2005.07]
Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. [2005]
The role of lipid management in diabetes. [2005.05]
Fibrates after the FIELD study: Some answers, more questions. [2006.12]
Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides. [2006.08]
[A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins] [2006.01]
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. [2006.07]
Meglitinide analogues: a review of clinical data focused on recent trials. [2006.04]
|
